Dear Mods
and to the person who insists on reporting the post as being off topic!
Please understand that there are a lot of KZA people who still hold MEIP through default of owning the old Novogen which became Kazia, just because you don't hold doesn't mean that other here don't still?
And seeing as how there is not an MEIP thread here because it is a US company, means that the only way we can stay informed, is here on the KZA thread.
Besides the drug they are talking about, is a sister drug to one of Kazia's, what is good for one may reflect on the other IMHO hopefully.
MEI Pharma (MEIP) Stock Takes a Hit but This Analyst Keeps the Faith
[email protected] (Ben Mahaney)
SmarterAnalystJuly 7, 2020
Investors of MEI Pharma (
MEIP) trudged off to the 4
th of July celebrations in a downbeat mood. In last week’s final session, shares declined by 18.5%.
The announcement that MEI and its collaboration partner, the Helsinn Group, prematurely ended a Phase 3 trial of pracinostat in acute myeloid leukemia (AML) was to blame for the sell-off. Interim data showed that the candidate’s use most likely won’t lead to better overall survival rates for AML patients.
While the news was greeted by surprise at investment firm BTIG, the trial’s abrupt ending does not overly concern company analyst
Thomas Shrader.
Contributing only 6% to the 5-star analyst’s model for the biotech, Shrader has another reason “patients and investors should care.” This reason is MEI’s potential treatment for patients with relapsed or refractory follicular lymphoma (FL), which is currently in a Phase 2 trial.
With the trial ongoing and expected to be fully enrolled by 1H21, Shrader’s base case involves the approval of ME-401 for FL in 2021. While MEI-401 is a PI3 delta inhibitor and belongs to a class of drugs that has been considered risky in the past, recent data supports Shrader’s bullish thesis.
“Overall, we see ME-401 in a good place in the B-Cell malignancy landscape with a very powerful
PI3K inhibitor they have learned to dose safely at a time when powerful drugs are increasingly viewed favorably in earlier lines. The drug's non-overlapping safety profile with other's in the overall B-Cell malignancy arena (BTK and MDM-2 inhibitors) also suggests combinations are more likely to have acceptable safety profiles… We still like the story, and we are raising our probability of success (POS) for ME-401 in FL to 75% from 60% based on recent data,” Shrader explained.
To this end, Shrader maintained a Buy rating along with a $5.50 price target. Investors could be taking home a 64% gain, should Shrader’s thesis play out over the coming months. (To watch Shrader’s track record,
click here)
The rest of the Street backs up the BTIG analyst’s call. All 6 analysts tracked over the past three months rate MEI a Buy. With an average price target of $9.75, there’s massive upside potential of 185% in the year ahead. (
See MEI Pharma stock analysis on TipRanks)
